Comparative Pharmacology
Head-to-head clinical analysis: ATIVAN versus CLONAZEPAM.
Head-to-head clinical analysis: ATIVAN versus CLONAZEPAM.
ATIVAN vs CLONAZEPAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Benzodiazepine that potentiates GABA-A receptor activity by increasing the frequency of chloride channel opening, leading to neuronal hyperpolarization and inhibition.
Enhances GABA-A receptor inhibitory neurotransmission by binding to benzodiazepine binding site, increasing frequency of chloride channel opening, leading to neuronal hyperpolarization.
2-3 mg orally divided 2-3 times daily; up to 10 mg/day. IV: 2 mg slow IV push, may repeat in 1-2 hours; max 10 mg/day. IM: 0.05 mg/kg (max 4 mg) 2-4 hours before procedure.
0.5 mg orally three times daily; maximum 20 mg/day
None Documented
None Documented
Terminal elimination half-life is 12–18 hours (mean ~14 h). In elderly, hepatic impairment, or obesity, half-life may be prolonged up to 30 hours.
Clinical Note
moderateClonazepam + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Clonazepam."
Clinical Note
moderateClonazepam + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Clonazepam."
Clinical Note
moderateClonazepam + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Clonazepam."
Clinical Note
moderateClonazepam + Fluconazole
Terminal elimination half-life: 19-60 hours (mean 30-40 hours); clinical context: long-acting benzodiazepine, allows once or twice daily dosing; accumulation occurs with repeated use.
Renal: lorazepam is primarily excreted as inactive glucuronide conjugates; <1% is excreted unchanged. Total: ~95% excreted in urine, ~5% in feces.
Renal: 50-70% as metabolites (mostly glucuronide conjugates), <2% unchanged; fecal: 10-20%; biliary: minor.
Category C
Category D/X
Benzodiazepine
Benzodiazepine
"The metabolism of Fluconazole can be decreased when combined with Clonazepam."